Organic Active Ingredients TRIZ Cases

Thrombosis treatment drugs induce antigen-specific humoral immunity, bypassing traditional TLR pathways to improve safety and efficacy.

Ribonucleotide agents bind to RIOK3 mRNA to decrease protein expression, upregulating fetal hemoglobin to address persistent sickle cell complications.

Segmented polymeric nanoparticles extend naloxone duration of action while reducing side effects from high doses.

Folate analog tracers target bacterial biosynthesis pathways to differentiate infection from inflammation, resolving diagnostic accuracy issues.

Antibodies against GRP78 prevent fungal invasion without Amphotericin B resistance or surgical debridement.

Epoxide hydrolase resolves racemic 2-butyl-2-ethyloxirane, achieving high enantioselectivity and yield while lowering synthesis costs.

Formula II cysteine protease inhibitors resolve side effects from bisphosphonate accumulation by enabling rapid clearance and flexible dosing regimens.

Sugar gel matrix with stearoyl inulin and specific esters creates a structured formulation system.

A hydroxypropyl cellulose matrix enables controlled drug release through gel formation.

Esterase-cleavable prodrugs overcome antioxidant degradation to enable oral blood-brain barrier passage.

A bladder perfusion pharmaceutical composition combines an immunological adjuvant with a chemotherapy drug to promote immune responses.

Modified antisense oligonucleotides inhibit SOD1 mRNA to slow amyotrophic lateral sclerosis progression.

Glucomannan protects APIs from oxidative degradation while the polymer matrix deters abuse.

Grafting murine CDRs onto a human framework reduces immunogenicity while preserving therapeutic efficacy against DR5-expressing tumors.

AA3-DLin ionizable lipids utilize Candida antarctica Lipase B catalyzed esterification to synthesize biodegradable compounds for mRNA delivery.

Amine substituted pyrimidine compounds inhibit Bmi-1 protein function and reduce its cellular levels.

Pharmaceutical compounds bind selectively to opioid receptors to provide targeted relief from pruritic conditions.

Analyzing AKT1, PRAS40, and AKT3 gene mutations overcomes drug resistance by enabling targeted PI3K or mTOR inhibitor selection.

Isoquinolinone derivatives modulate lipid metabolism by inhibiting FABP4 and FABP5, improving physicochemical properties over existing inhibitors.

PDGFRα inhibitors improve median overall survival in PDGFRβ negative cancer by enabling precise patient stratification through antibody-based detection.

Buffers raise stomach microenvironment pH, enabling hydrogel swelling that fails in acidic conditions.

Salsolinol and reticuline derivatives activate AMPK to lower blood glucose levels and treat metabolic diseases.

Hydroxycitrate stereoisomers dissolve calcium oxalate crystals, preventing stone recurrence without adverse effects.

Agents increasing hexadecadienoate or decreasing dimethylglycine counteract metabolic shifts after smoking cessation.

Targeting JAK/STAT pathways overcomes chemoresistance and radioresistance in prostate cancer treatment.

A fixed-dose oral tablet combines erodible stimulant and non-stimulant materials within a substrate structure to deliver controlled release profiles.

Measuring s100A9 concentrations enables clinicians to select lenalidomide or erythropoietin therapies for patients lacking chromosome 5q deletions.

Novel LIF/LIFR inhibitors overcome limited oral bioavailability by modifying chemical structures to enhance absorption and maintain signaling inhibition.

Selective PKR activation shifts the 2,3-DPG to ATP ratio in erythrocytes, increasing hemoglobin oxygen affinity to reduce sickling.

Systemic oligonucleotides down-regulate MTHFD2 expression, addressing inadequate treatment efficacy for advanced prostate cancer cases.

A p38 kinase inhibitor stabilizes monoamine transporter activity.

Tomentosin targets lymphoid tumor cells to inhibit proliferation while sparing healthy tissue from toxicity.

Composite granule formulation resolves the contradiction between tablet mechanical resistance and rapid disintegration rate.

Formula I compounds inhibit mTOR pathways to regress skin lesions while avoiding the inflammation caused by conventional therapies.

Synthetic glycan conjugates induce specific immune reactions against RM2 antigens.

Stelliferin compound from marine Porifera extracts inhibits leukemic stem cell niche formation to enhance antitumor agent susceptibility.

PIAS3 protein modulates T cell differentiation pathways to regulate immune responses.

Dynamic measurement resource allocation distinguishes active and dormant cell states to maintain accuracy despite rapid interference changes.

N-cocoyl alanine increases survivin expression in basal keratinocytes to maintain epidermal stem cell populations.

A chromone scaffold derivative triggers replicative senescence and apoptosis in malignant cells.

Clioquinol analogues inhibit SARS-CoV-2 infection through zinc chelation and Spike protein binding disruption, addressing limited therapeutic options.

Glycerol and lauryl lactate in a polymeric vehicle maintain steady-state flux for three days, resolving oral administration compliance issues.

Analyzing placental NHIP methylation patterns enables prenatal ASD risk identification and targeted vitamin intervention.

Isoquinoline compounds inhibit MAP4K4 activity, disrupting angiogenesis and reducing tumor growth without affecting unrelated biological processes.

A buccal tablet formulation delivers avanafil through the oral mucosa to achieve systemic absorption.